Seeking Alpha 3/22/13 ACAD TO GO Higher Based on Untreatable Diseases. LINK
Seeking Alpha 3/22/13
Ultimately I think that Acadia could see a lot more interest in the next few trading sessions as investors think about the huge prospects that this drug could have in an untreatable neurodegenerative disease, and while we move closer to a potential NDA submission. These results also bode well for Pimavanserin's otherdevelopment programs, which include Pimavanserin for the treatment of schizophrenia and Alzheimer's Disease Psychosis (ADP).